Manganese and Parkinson's disease: A critical review and new findings

Environmental Health Perspectives

Volumn 118, Issue 8, 2010, Pages 1071-1080

  Guilarte, Tomás R ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Basal ganglia; Dopamine; Humans; Manganese; Movement disorder; Neuroimaging; Neurotoxicity; Nonhuman primates; Parkinson's disease; Striatum

Indexed keywords

LEVODOPA; MANGANESE; METHCATHINONE;

CAUSAL ATTRIBUTION; CLINICAL FEATURE; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; DRUG TREATMENT FAILURE; ENVIRONMENTAL EXPOSURE; GAIT DISORDER; HUMAN; INTOXICATION; INTRAVENOUS DRUG ABUSE; LIVER DISEASE; LONG TERM EXPOSURE; NERVE CELL DEGENERATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL EXPOSURE; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TOXICOKINETICS; TREMOR;

ANIMALS; BASAL GANGLIA; DIAGNOSIS, DIFFERENTIAL; ENVIRONMENTAL EXPOSURE; HUMANS; MANGANESE; MANGANESE POISONING; NERVE DEGENERATION; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PRIMATES;

PRIMATES;

EID: 77956084101     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.0901748     Document Type: Review

References (83)

1. Aggarwal A, Vaidya S, Shah S, Singh J, Desai S, Bhatt M. 2006. Reversible parkinsonism and T1W pallidal hyperintensities in acute liver failure. Mov Disord 21:1986-1990.
2. Anderson JG, Cooney PT, Erikson KM. 2007. Inhibition of DAT function attenuates manganese accumulation in the globus pallidus. Environ Toxicol Pharmacol 23:179-184.
3. 11C]-raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2 receptors. Neurology 44:1325-1329.
4. Bergeron M, Reader TA, Layrargues GP, Butterworth RF. 1989. Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem Res 14:853-859.
5. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 20:415-455.
6. Bird ED, Anton AH, Bullock B. 1984. The effect of manganese inhalation on basal ganglia dopamine concentrations in rhesus monkey. Neurotoxicology 5:59-65.
7. Bowler RM, Koller W, Schulz PE. 2006. Parkinsonism due to manganism in a welder: neurological and neuropsychological sequelae. Neurotoxicology 27:327-332.
8. Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, et al. 1992. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy measured with 11C-raclopride and positron emission tomography. Ann Neurol 31:184-192.
9. Burkhard PR, Delavelle J, Du Pasquier R, Spahr L. 2003. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol 60:521-528.
10. Butterworth RF, Spahr L, Fontaine S, Layrargues GP. 1995. Manganese toxicity, dopaminerigc dysfunction and hepatic encephalopathy. Metab Brain Dis 10:259-267.
11. Chandra SV, Srivastava RS, Shukla GS. 1979. Regional distribution of metals and biogenic amines in the brain of monkeys exposed to manganese. Toxicol Lett 4:189-192.
12. Chen MK, Kuwabara H, Zhou Y, Adams RJ, Brasic JR, McGlothan JL, et al. 2008. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 105:78-90.
13. Chen MK, Lee JS, McGlothan JL, Furukawa E, Adams RJ, Alexander M, et al. 2006. Acute manganese administration alters dopamine transporter levels in the nonhuman primate striatum. Neurotoxicology 27:229-236.
14. Colosimo C, Guidi M. 2009. Parkinsonism due to ephedrone neurotoxicity: a case report. Eur J Neurol 16: e114-e115.
15. Cook DG, Fahn S, Brait KA. 1974. Chronic manganese intoxication. Arch Neurol 30:59-64.
16. Couper J. 1837. On the effects of black oxide of manganese when inhaled in the lungs. Br Ann Med Pharmacol 1:41-42.
17. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889-909.
18. de Bie RM, Gladstone RM, Strafella AP, Ko JH, Lang AE. 2007. Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. Arch Neurol 64:886-889.
19. Dorman DC, Struve MF, Wong BA, Dye JA, Robertson ID. 2006. Correlation of brain magnetic resonance imaging changes with pallidal manganese concentrations in rhesus monkeys following subchronic manganese inhalation. Toxicol Sci 92:219-227.
20. Ehringer H, Hornykiewicz O. 1960. Verteilung von Noradrenalin und Dopamin (3-hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalem Systems [in German]. Klin Wochenschr 38:1236-1239.
21. Eriksson H, Gillberg PG, Aquilonius SM, Hedstrom KG, Heilbronn E. 1992a. Receptor alterations in manganese intoxicated monkeys. Arch Toxicol 66:359-364.
22. Eriksson H, Mägiste K, Plantin LO, Fonnum F, Hedström KG, Theodorsson-Norheim E, et al. 1987. Effects of manganese oxide on monkeys as revealed by a combined neurochemical, histological and neurophysiological evaluation. Arch Toxicol 61:46-52.
23. Eriksson H, Tedfoff J, Thuomas KA, Aquilonius SM, Hartvig P, Fasth KJ, et al. 1992b. Manganese induced brain lesions in Macaca fascicularis as revealed by positron emission tomography and magnetic resonance imaging. Arch Toxicol 66:403-407.
24. Faviani G, Rogacheski E, Wiederkehr JC, Khouri J, Cianfarano A. 2007. Liver transplantation in a patient with rapid onset parkinsonism-dementia complex induced by manganism secondary to liver failure. Arq Neuropsiquiatr 65:685-688.
25. Felicio AC, Shih MC, Godeiro-Junior C, Andrade LA, Bressan RA, Ferraz HB. 2009. Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainly. Neurologist 15:6-16.
26. Gelb DJ, Oliver E, Gilamn S. 1999. Diagnosis criteria for Parkinson disease. Arch Neurol 56:33-39.
27. Guilarte TR, Burton NC, McGlothan JL, Verina T, Zhou Y, Alexander M, et al. 2008. Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem 107:1236-1247.
28. Guilarte TR, Chen MK, McGlothan JL, Verina T, Wong DF, Zhou Y, et al. 2006a. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed nonhuman primates. Exp Neurol 202:381-390.
29. Guilarte TR, McGlothan JL, Degaonkar M, Chen MK, Barker PB, Syversen T, et al. 2006b. Evidence for cortical dysfunction and widespread manganese accumulation in the nonhuman primate brain following chronic manganese exposure: a 1H-MRS and MRI study. Toxicol Sci 94:351-358.
30. Hornykiewicz O. 2006. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm (suppl):9-15.
31. Huang CC. 2007. Parkinsonism induced by chronic manganese intoxication-an experience in Taiwan. Chang Gung Med J 30:385-395.
32. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. 2002. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861-870.
33. Hughes AJ, Daniel SE, Lees AJ. 1993. The clinical features of Parkinson's disease in 100 histological proven cases. Adv Neurol 60:595-599.
34. Ingersoll RT, Montgomery EB Jr, Aposhian HV. 1999. Central nervous system toxicity of manganese. II: cocaine or reserpine inhibit manganese concentration in the rat brain. Neurotoxicology 20:467-476.
35. Jankovic J. 2008. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368-376.
36. Josephs KA, Ahlskog JE, Klos KJ, Kumar N, Fealey RD, Trenerry MR, et al. 2005. Neurologic manifestations in welders with pallidal MRI T1 hyperintensity. Neurology 64:2033-2039.
37. Kenangil G, Ertan S, Sayilir I, Ozekmekçi S. 2006. Progressive motor syndrome in a welder with pallidal T1 hyperintensity on MRI: a two year follow-up. Mov Disord 21:2197-2200.
38. Kessler KR, Wunderlich G, Hefter H, Seitz RJ. 2003. Secondary progressive chronic manganism associated with markedly decreased striatal D2 receptor density. Mov Disord 18:217-218.
39. Kim J, Kim J-M, Kim YK, Shin JW, Choi SH, Kim SE, et al. 2007. Dopamine transporter SPECT of a liver cirrhotic with atypical parkinsonism. Ind Health 45:497-500.
40. Kim Y, Kim JM, Kim JW, Yoo CI, Lee CR, Lee JH, et al. 2002. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean? Mov Disord 17:568-575.
41. Klos KJ, Ahlskog JE, Josephs KA, Fealey RD, Cowl CT, Kumar N. 2005. Neurologic spectrum of chronic liver failure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity. Arch Neurol 62:1385-1390.
42. Klos KJ, Ahlskog JE, Kumar N, Cambern S, Butz J, Burritt M, et al. 2006. Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity. Neurology 67:1984-1989.
43. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451.
44. Lee JW. 2000. Manganese intoxication. Arch Neurol 57:597-599.
45. Lees AJ, Hardy J, Revesz T. 2009. Parkinson's disease. Lancet 373:2055-2066.
46. Leenders KL. 2003. Significance of nonpresynaptic SPECT tracer methods in Parkinson's disease. Mov Disord 18(suppl 7):S39-S42.
47. Louis ED, Klatka LA, Liu Y, Fahn S. 1997. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 48:376-380.
48. Lu CS, Huang CC, Chu NS, Calne DB. 1994. Levodopa failure in chronic manganism. Neurology 44:1600-1602.
49. May CH, Guilarte TR, Wagner HN Jr, Vogel S. 1994. Intrastriatal infusion of lisuride-a potential treatment for Parkinson's disease? Behavioral and autoradiographic studies in 6-OHDA lesioned rats. Neurodegeneration 3:305-313.
50. Mena I, Marin O, Fuenzalida S, Cotzias GC. 1967. Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology 17:128-136.
51. Meral H, Kutukcu Y, Atmaca B, Ozer F, Hamamcioglu K. 2007. Parkinsonism caused by chronic usage of intravenous potassium permanganate. Neurologist 13:92-94.
52. Mousseau DD, Perney P, Layrargues P, Butterworth RF. 1993. Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy. Neurosci Lett 162:192-196.
53. Nagatomo S, Umehara F, Hanada K, Nobuhara Y, Takenaga S, Arimura K, et al. 1999. Manganese intoxication during total parenteral nutrition: report of two cases and review of the literature. J Neurol Sci 162:102-105.
54. Neff NH, Barrett RE, Costa E. 1969. Selective depletion of caudate nucleus dopamine and serotonin during chronic manganese dioxide administration to squirrel monkeys. Experientia 25:1140-1141.
55. Newland MC, Ceckler TL, Kordower JH, Weiss B. 1989. Visualizing manganese in the primate basal ganglia with magnetic resonance imaging. Exp Neurol 106:251-258.
56. Newland MC, Weiss B. 1992. Persistent effects of manganese on effortful responding and their relationship to manganese accumulation in the primate globus pallidus. Toxicol Appl Pharmacol 113:87-97.
57. Olanow CW, Good PF, Shinotoh H, Hewitt KA, Vingerhoets F, Snow BJ, et al. 1996. Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology 46:492-498.
58. Parkinson J. 1817. An Essay on the Shaking Palsy. Available: http://www.gutenberg.org/files/23777/23777-h/23777-h.htm [accessed 3 June 2010].
59. Pentschew A, Ebner FF, Kovatch RM. 1963. Experimental manganese encephalopathy in monkeys. A preliminary report. J Neuropathol Exp Neurol 22:488-499.
60. Perl DP, Olanow CW. 2007. The neuropathology of manganese-induced Parkinsonism. J Neuropathol Exp Neurol 66:675-682.
61. 18F]FDOPA PET and clinical features in parkinsonism due to manganism. Mov Disord 20:492-496.
62. Racette BA, McGee-Minnich L, Moerlein SM, Mink JW, Videen TO, Perlmutter JS. 2001. Welding related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 56:8-13.
63. Rajput AH, Rozdilsky B, Ang L. 1991. Occurrence of resting tremor in Parkinson's disease. Neurology 41:1298-1299.
64. Ravina B, Siderowf A, Farrar J, Hurtig H. 2001. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 57:936-937.
65. Rinne UK, Laithinen A, Rinne JO, Nágren K, Bergman J, Ruotsalainen U. 1990. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 5:55-59.
66. Sadak AH, Schulz PE. 2001. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 57:1738-1739.
67. Sadek AH, Rauch R, Schulz PE. 2003. Parkinsonism due to manganism in a welder. Int J Toxicol 22:393-401.
68. Sanotsky Y, Lesyk R, Fedoryshyn L, Komnatska I, Matviyenko Y, Fahn S. 2007. Manganic encephalopathy due to "ephedrone" abuse. Mov Disord 22:1337-1343.
69. Savitt JM, Dawson VL, Dawson TM. 2006. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116:1744-1754.
70. Schaumberg HH, Herskovitz S, Cassano VA. 2006. Occupational manganese neurotoxicity provoked by hepatitis C. Neurology 67:322-323.
71. Schneider JS, Decamp E, Clark K, Bouquio C, Syversen T, Guilarte TR. 2009. Effects of chronic manganese exposure on working memory in nonhuman primates. Brain Res 1258:86-95.
72. Schneider JS, Decamp E, Koser AJ, Fritz S, Gonczi H, Syversen T, et al. 2006. Effects of chronic manganese exposure on cognitive and motor functioning in nonhuman primates. Brain Res 1118:222-231.
73. Selikhova M, Fedoryshyn L, Matviyenko Y, Komnatska I, Kyrylchuk M, Krolicki L, et al. 2008. Parkinsonism and dystonia caused by illicit use of ephedrone-a longitudinal study. Mov Disord 23:2224-2231.
74. Shinotoh H, Snow BF, Hewitt KA, Pate BD, Doudet D, Nugent R, et al. 1995. MRI and PET studies of manganese-intoxicated monkeys. Neurology 45:1199-1204.
75. Sikk K, Taba P, Haldre S, Bergquist J, Nyholm D, Zjablov G, et al. 2007. Irreversible motor impairment in young addicts-ephedrone, manganism or both? Acta Neurol Scand 115:385-389.
76. Stepens A, Logina I, Liguts V, Aldins P, Eksteina I, Platkäjis A, et al. 2008. A Parkinsonian syndrome in methcathinone users and the role of manganese. N Engl J Med 358:1009-1017.
77. Struve MF, McManus BE, Wong BA, Dorman DC. 2007. Basal ganglia neurotransmitter concentrations in rhesus monkeys following subchronic manganese sulfate inhalation. Am J Ind Med 50:772-778.
78. Tolosa E, Wenning G, Poewe W. 2006. The diagnosis of Parkinson's disease. Lancet Neurol 5:75-86.
79. Varlibas F, Delipoyraz I, Yuksel G, Filiz G, Tireli H, Gecim NO. 2009. Neurotoxicity following chronic intravenous use of "Russian cocktail." Clin Toxicol (Phila) 47:157-160.
80. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. 1997. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 41:58-64.
81. Wakabayashi K, Tanji K, Mori F, Takahashi H. 2007. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27:494-506.
82. Yamada M, Ohno S, Okayasu I, Okeda R, Hatakeyama S, Watanabe H, et al. 1986. Chronic manganese poisoning: a neuropathological study with determination of manganese distribution in the brain. Acta Neuropathol 70:273-278.
83. Zhou Y, Chen M-K, Endres CJ, Ye W, Brasic JR, Alexander M, et al. 2006. An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. Neuroimage 33:550-563.